GAL-101
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for GAL-101, covering 2026-02-06 to 2026-02-06. Get the full timeline:
Most recent: Clinical Trial Update: A Phase 2 Efficacy and Safety Study of GAL-101, 2% Ophthalmic Solution in Non-foveal Geographic Atrophy Secondary to Non-neovascular AMD [Phase 2]